Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

2 terminated/withdrawn out of 12 trials

Success Rate

81.8%

-4.7% vs industry average

Late-Stage Pipeline

8%

1 trials in Phase 3/4

Results Transparency

78%

7 of 9 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 2
6(54.5%)
Phase 1
4(36.4%)
Phase 3
1(9.1%)
11Total
Phase 2(6)
Phase 1(4)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT04292743Phase 1Completed

Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma

Role: collaborator

NCT03267030Phase 2Completed

Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase

Role: collaborator

NCT03665441Phase 3Completed

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC

Role: lead

NCT03674242Phase 2Terminated

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)

Role: lead

NCT01810705Phase 2Completed

GRASPA Treatment for Patients With Acute Myeloblastic Leukemia

Role: lead

NCT01518517Phase 2Completed

GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia

Role: lead

NCT01523782Phase 2Completed

Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia

Role: lead

NCT01523808Phase 1Completed

Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer

Role: lead

NCT02197650Unknown

Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase

Role: lead

NCT02195180Phase 2Completed

Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma

Role: lead

NCT01910428Phase 1Terminated

L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL

Role: lead

NCT00723346Phase 1Completed

Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia

Role: lead

All 12 trials loaded